SG11201906132UA - Insoluble complex or solvate thereof, pharmaceutical composition and use thereof - Google Patents
Insoluble complex or solvate thereof, pharmaceutical composition and use thereofInfo
- Publication number
- SG11201906132UA SG11201906132UA SG11201906132UA SG11201906132UA SG 11201906132U A SG11201906132U A SG 11201906132UA SG 11201906132U A SG11201906132U A SG 11201906132UA SG 11201906132U A SG11201906132U A SG 11201906132UA
- Authority
- SG
- Singapore
- Prior art keywords
- solvate
- pharmaceutical composition
- insoluble complex
- insoluble
- complex
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
- C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710188001 | 2017-03-27 | ||
PCT/CN2018/080424 WO2018177232A1 (en) | 2017-03-27 | 2018-03-26 | Poorly soluble complex or solvate thereof, pharmaceutical composition, and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201906132UA true SG11201906132UA (en) | 2019-10-30 |
Family
ID=63675241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201906132U SG11201906132UA (en) | 2017-03-27 | 2018-03-26 | Insoluble complex or solvate thereof, pharmaceutical composition and use thereof |
Country Status (17)
Country | Link |
---|---|
US (1) | US11084790B2 (en) |
EP (1) | EP3486233B1 (en) |
JP (1) | JP6923122B2 (en) |
KR (1) | KR102248445B1 (en) |
CN (1) | CN109996787B (en) |
AU (1) | AU2018241564B2 (en) |
CA (1) | CA3049220C (en) |
DK (1) | DK3486233T3 (en) |
EA (1) | EA039449B1 (en) |
ES (1) | ES2866401T3 (en) |
HU (1) | HUE053472T2 (en) |
PH (1) | PH12019501560A1 (en) |
PL (1) | PL3486233T3 (en) |
PT (1) | PT3486233T (en) |
SG (1) | SG11201906132UA (en) |
TW (1) | TWI740045B (en) |
WO (1) | WO2018177232A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110483372A (en) * | 2018-05-14 | 2019-11-22 | 南京诺瑞特医药科技有限公司 | The salt of Bupivacaine |
CN111983052B (en) * | 2020-07-24 | 2023-03-31 | 合肥诺明药物安全研究有限公司 | Quantitative analysis method for blood concentration of HYR-PB21 effective ingredient |
KR20230133595A (en) | 2022-03-11 | 2023-09-19 | 한국한의약진흥원 | Composition for maintaining stability of serotonin contained in Vespa Velutina venom |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003099293A1 (en) * | 2002-05-23 | 2003-12-04 | Danmarks Farmaceutiske Universitet | Pharmacologically active salts |
CA2529503A1 (en) * | 2003-06-20 | 2004-12-29 | Royer Biomedical, Inc. | Drug polymer complexes |
DK1809329T3 (en) * | 2004-09-17 | 2012-04-02 | Durect Corp | CONTINUOUS LOCAL ANAESTIC COMPOSITION CONTAINING SAIB |
US8920843B2 (en) | 2007-11-07 | 2014-12-30 | Svip5 Llc | Slow release of organic salts of local anesthetics for pain relief |
EP2398468B1 (en) | 2009-02-17 | 2016-11-30 | KRKA, D.D., Novo Mesto | Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation |
CZ2009762A3 (en) | 2009-11-16 | 2011-05-25 | Zentiva, K. S. | Novel salts of 5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate known under unprotected name prasugrel and process of their preparation |
CN104370934B (en) * | 2013-08-13 | 2018-04-06 | 上海科胜药物研发有限公司 | A kind of prasugrel salt and preparation method thereof |
CN107848973A (en) * | 2015-09-01 | 2018-03-27 | 四川海思科制药有限公司 | The dimethylaniline formyl piperidine crystal of 1 propyl group of S () 2 ', 6 ' and its sustained release preparation |
EP3558279A4 (en) | 2016-12-26 | 2020-12-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
-
2018
- 2018-03-26 DK DK18777940.0T patent/DK3486233T3/en active
- 2018-03-26 ES ES18777940T patent/ES2866401T3/en active Active
- 2018-03-26 CA CA3049220A patent/CA3049220C/en active Active
- 2018-03-26 KR KR1020197018905A patent/KR102248445B1/en active IP Right Grant
- 2018-03-26 HU HUE18777940A patent/HUE053472T2/en unknown
- 2018-03-26 SG SG11201906132U patent/SG11201906132UA/en unknown
- 2018-03-26 CN CN201880002853.5A patent/CN109996787B/en active Active
- 2018-03-26 JP JP2019535272A patent/JP6923122B2/en active Active
- 2018-03-26 US US16/325,997 patent/US11084790B2/en active Active
- 2018-03-26 PT PT187779400T patent/PT3486233T/en unknown
- 2018-03-26 EP EP18777940.0A patent/EP3486233B1/en active Active
- 2018-03-26 EA EA201990419A patent/EA039449B1/en unknown
- 2018-03-26 PL PL18777940T patent/PL3486233T3/en unknown
- 2018-03-26 AU AU2018241564A patent/AU2018241564B2/en active Active
- 2018-03-26 WO PCT/CN2018/080424 patent/WO2018177232A1/en unknown
- 2018-05-22 TW TW107117420A patent/TWI740045B/en active
-
2019
- 2019-07-02 PH PH12019501560A patent/PH12019501560A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA039449B1 (en) | 2022-01-28 |
TWI740045B (en) | 2021-09-21 |
CA3049220C (en) | 2022-03-29 |
AU2018241564A1 (en) | 2019-05-30 |
JP6923122B2 (en) | 2021-08-18 |
KR102248445B1 (en) | 2021-05-04 |
EP3486233A4 (en) | 2020-04-08 |
TW201940170A (en) | 2019-10-16 |
WO2018177232A1 (en) | 2018-10-04 |
US20210087144A1 (en) | 2021-03-25 |
PT3486233T (en) | 2021-03-18 |
PL3486233T3 (en) | 2021-06-28 |
HUE053472T2 (en) | 2021-06-28 |
AU2018241564B2 (en) | 2020-07-02 |
US11084790B2 (en) | 2021-08-10 |
EA201990419A1 (en) | 2019-09-30 |
KR20190101980A (en) | 2019-09-02 |
JP2020515513A (en) | 2020-05-28 |
ES2866401T3 (en) | 2021-10-19 |
EP3486233B1 (en) | 2021-01-27 |
CN109996787A (en) | 2019-07-09 |
PH12019501560A1 (en) | 2020-02-24 |
CA3049220A1 (en) | 2018-10-04 |
CN109996787B (en) | 2022-07-05 |
DK3486233T3 (en) | 2021-03-15 |
EP3486233A1 (en) | 2019-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL269061A (en) | Pharmaceutical composition comprising selexipag | |
EP3434285A4 (en) | Pharmaceutical composition and use thereof | |
HK1256674A1 (en) | Deuterium-modified brigatinib derivatives, pharmaceutical compositions comprising same, and use thereof | |
IL271226A (en) | Pharmaceutical formulation | |
IL273339A (en) | Griseofulvin compound and pharmaceutical use thereof | |
IL248785B (en) | N-[1,5-dimethyl-3-oxo-(2,3-dihydro-1h-pyrazol-4-yl)]-4-methyl-isoxazole-3-carboxamide derivatives and pharmaceutical compositions comprising said derivatives | |
PT3606511T (en) | Pharmaceutical composition comprising lenvatinib mesylate | |
IL248773B (en) | 1,6-naphthyridine-4,5-dione derivatives and pharmaceutical compositions comprising them | |
SG11201906132UA (en) | Insoluble complex or solvate thereof, pharmaceutical composition and use thereof | |
EP3773654C0 (en) | Polypharmaceutical drug compositions and related methods | |
HK1245113A1 (en) | Pharmaceutical compositions and use thereof | |
FI3601277T3 (en) | Pharmaceutical formulation | |
IL262929B1 (en) | Composition, and application and pharmaceutical preparation thereof | |
IL275144A (en) | Pharmaceutical formulation | |
ZA202000959B (en) | Adamantylmethylamine derivative and use thereof as pharmaceutical | |
EP3718543A4 (en) | Pharmaceutical composition and use thereof | |
IL237283A0 (en) | Dldh, derivatives thereof and formulations comprising same for use in medicine | |
HK1254527A1 (en) | Pharmaceutical formulation and use thereof | |
GB201713920D0 (en) | Pharmaceutical compositions and uses thereof | |
GB201812022D0 (en) | Pharmaceutical methods and compositions | |
GB201719873D0 (en) | Pharmaceutical formulation |